Elaine Marie Hylek, MD, MPH
November 28th, 2011
Roundtable: Two Trials, Two Anticoagulants, Many Implications
Samuel Goldhaber, MD, Elaine Marie Hylek, MD, MPH and Christian Thomas Ruff, MD, MPH
Three experts weigh in on findings from the ATLAS ACS 2-TIMI 51 and ADOPT trials.
March 18th, 2011
Dabigatran Dialogue: Two Experts Answer Our Questions and Yours
Samuel Goldhaber, MD and Elaine Marie Hylek, MD, MPH
In a series of blog posts on CardioExchange, Samuel Goldhaber, Director of the Venous Thromboembolism Research Group in the Cardiovascular Division at Brigham and Women’s Hospital, has been guiding us on best practices around dabigatran. Recently, he teamed up with Elaine Hylek, Director of the Thrombosis and Anticoagulation Service at Boston University School of Medicine, […]
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension